Skip to Main Content

Paper Details

Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML.
Blood Adv
10
2023
AML, MDS, RAR, RARA, RARA mRNA, RARA-high but not RARA-low preclinical AML models, RARA-negative patients, Tamibarotene, acute myeloid leukemia, azacitidine, myelodysplastic syndromes, myelosuppression, non-acute promyelocytic leukemia, patient, patients, peripheral blasts, retinoic acid, retinoic acid receptor alpha, retinoic acid receptor alpha (RARA) gene, superenhancer, tamibarotene
Author NameAffiliation
Thomas CluzeauCote d'Azur Universite, Centre Hospitalier Universitaire de Nice Hopital
Rachel J CookKnight Cancer Institute, Oregon Health & Science University
David A RizzieriNovant Health Cancer Institute
Thorsten BraunCentre Hospitalier Universitaire Hopital Avicenne
John Graeme HodgsonSyros Pharmaceuticals
  • 1 - 5

Datasets

Release 1.2